Advanced search
Publication Cover
Neurological Research
A Journal of Progress in Neurosurgery, Neurology and Neurosciences
Volume 28, 2006 - Issue 3: Multiple Sclerosis
Submit an article Journal homepage
22
Views
20
CrossRef citations to date
0
Altmetric
Articles

Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis

Jeffrey L. BennettDepartments of Neurology and OphthalmologyUniversity of Colorado at Denver and Health Sciences Center, USA
Pages 291-298 | Published online: 02 Dec 2013

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Michele Faulkner. (2015) Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opinion on Drug Safety 14:11, pages 1737-1748.
Read now
Alireza Minagar. (2006) Multiple sclerosis: current knowledge and future directions. Neurological Research 28:3, pages 227-229.
Read now

Articles from other publishers (18)

Nadja Demitrowitz & Tjalf Ziemssen. (2020) Multiple Sklerose: Neuroinflammation und -degeneration Hand in Hand. Kompass Autoimmun 2:4, pages 147-150.
Crossref
Marian Brennan & Dermot Cox. 2014. I Domain Integrins. I Domain Integrins 157 178 .
James T Rosenbaum. (2010) Future for biological therapy for uveitis. Current Opinion in Ophthalmology 21:6, pages 473-477.
Crossref
Amer M. Awad & Olaf Stüve. (2010) IMMUNOPATHOGENESIS OF MULTIPLE SCLEROSIS. CONTINUUM: Lifelong Learning in Neurology 16, pages 166-180.
Crossref
Dermot Cox, Marian Brennan & Niamh Moran. (2010) Integrins as therapeutic targets: lessons and opportunities. Nature Reviews Drug Discovery 9:10, pages 804-820.
Crossref
Patcharica Meteesatien, Scott E Plevy, Justin D. Fender & Yuri Fedoriw. (2010) Circulating Blasts in a Crohn’s Patient Treated With Natalizumab. Laboratory Medicine 41:8, pages 453-456.
Crossref
Jeffrey L. Bennett & Olaf Stüve. (2009) Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology 32:3, pages 121-132.
Crossref
John W. Rose, John F. Foley & Noel G. Carlson. (2009) Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology 11:3, pages 211-220.
Crossref
John W. Rose, John Foley & Noel Carlson. (2008) Monoclonal antibody treatments for multiple sclerosis. Current Neurology and Neuroscience Reports 8:5, pages 419-426.
Crossref
Karen Yao, Susan Gagnon, Nahid Akhyani, Elizabeth Williams, Julie Fotheringham, Elliot Frohman, Olaf Stuve, Nancy Monson, Michael K. Racke & Steven Jacobson. (2008) Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients. PLoS ONE 3:4, pages e2028.
Crossref
Raija L.P. Lindberg, Lutz Achtnichts, Francine Hoffmann, Jens Kuhle & Ludwig Kappos. (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. Journal of Neuroimmunology 194:1-2, pages 153-164.
Crossref
Irene Cortese & Henry F. McFarland. 2008. Clinical Immunology. Clinical Immunology 963 975 .
Jonathan Riley, Alejandro Spiotta & Nicholas Boulis. (2007) Experimental therapeutic approaches to peripheral nerve tumors. Neurosurgical Focus 22:6, pages 1-17.
Crossref
Tracy L. Deem, Hiam Abdala-Valencia & Joan M. Cook-Mills. (2007) VCAM-1 Activation of Endothelial Cell Protein Tyrosine Phosphatase 1B. The Journal of Immunology 178:6, pages 3865-3873.
Crossref
Venugopal Govindappa, Sarah Hicks, Melvin Wichter & Meenakshi Jolly. (2007) Progressive multifocal leukoencephalopathy in systemic lupus erythematosus. Arthritis Care & Research 57:2, pages 352-354.
Crossref
Olaf Stüve & Jeffrey L. Bennett. (2007) Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri®) in Inflammatory Diseases. CNS Drug Reviews 13:1, pages 79-95.
Crossref
John M. Vierling. 2007. Liver Immunology. Liver Immunology 391 407 .
Hiam Abdala-Valencia & Joan M. Cook-Mills. (2006) VCAM-1 Signals Activate Endothelial Cell Protein Kinase Cα via Oxidation. The Journal of Immunology 177:9, pages 6379-6387.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.